Jiangsu Nhwa Pharmaceutical Co., LTD
Symbol: 002262.SZ
SHZ
25.16
CNYMarktpreis heute
23.9060
P/E-Verhältnis
2.4589
PEG-Verhältnis
25.35B
MRK Kapital
- 0.00%
DIV Rendite
Jiangsu Nhwa Pharmaceutical Co., LTD (002262-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13635.22 | 3493.9 | 2984.2 | 2666 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 5823.3 | 1335 | 1452 | 1058.4 | |||||||||||||||||||
balance-sheet.row.net-receivables | 4452.03 | 1091.7 | 937.3 | 757.7 | |||||||||||||||||||
balance-sheet.row.inventory | 2592.65 | 628.6 | 716.3 | 604.3 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 94.68 | 40.3 | 12.6 | 15.1 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 20774.58 | 5254.6 | 4650.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5602.51 | 1539.5 | 1303.7 | 1158.3 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -1914.2 | 157.3 | -1333.4 | -928 | |||||||||||||||||||
balance-sheet.row.tax-assets | 218.31 | 58.3 | 37.5 | 30.7 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3137.07 | 42.3 | 1599.7 | 1225.5 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 8127.38 | 2073.6 | 1831.3 | 1654 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.account-payables | 1056.28 | 216.3 | 255.7 | 267.2 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 380.84 | 136.8 | 50.6 | 63 | |||||||||||||||||||
balance-sheet.row.tax-payables | 542.85 | 84.1 | 143.6 | 125.7 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 57.51 | 0.2 | 42.1 | 47.9 | |||||||||||||||||||
Deferred Revenue Non Current | 223.83 | 53.9 | 58 | 63.6 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 40.67 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 892.5 | 434.5 | 426.8 | 2.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 329.6 | 50.2 | 103 | 111.5 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 130.84 | 35.6 | 41.9 | 47.7 | |||||||||||||||||||
balance-sheet.row.total-liab | 3568.94 | 864.2 | 897 | 793.5 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 4030.35 | 1007.6 | 1007.6 | 1007.6 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 18875.34 | 4813 | 3978.4 | 3366.1 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2478.66 | 611.2 | 617.6 | 528.3 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 21.03 | 2.3 | 18.7 | 18.7 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 25405.37 | 6434.1 | 5622.2 | 4920.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.minority-interest | -126.22 | -24 | -37.5 | -17 | |||||||||||||||||||
balance-sheet.row.total-equity | 25279.15 | 6410.1 | 5584.8 | 4903.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 28901.96 | - | - | - | |||||||||||||||||||
Total Investments | 3909.1 | 1492.3 | 118.6 | 130.4 | |||||||||||||||||||
balance-sheet.row.total-debt | 512.6 | 172.6 | 92.8 | 110.9 | |||||||||||||||||||
balance-sheet.row.net-debt | -7299.32 | -1986.4 | -1439.4 | -1496.7 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1074.77 | 1036.9 | 880.4 | 798 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 9.99 | 175.1 | 148.7 | 135.1 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -23.2 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -528.7 | 4 | 2.5 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -144.64 | -178.6 | -160.6 | -251.1 | |||||||||||||||||||
cash-flows.row.account-receivables | -199.06 | -199.1 | -155.3 | -122.9 | |||||||||||||||||||
cash-flows.row.inventory | 54.43 | 54.4 | -128.2 | -205.9 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | -33.9 | 126.9 | 77.1 | |||||||||||||||||||
cash-flows.row.other-working-capital | -0.01 | 0 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -49.47 | 569 | -7.5 | 16.1 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 890.65 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 1.16 | 1.4 | 0.1 | 0.2 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -6453.5 | -6453.5 | -5527.5 | 0.3 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 6518.29 | 6490.5 | 32.4 | 34.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -313.73 | 0 | 5133.9 | -221.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -595.85 | -335.6 | -688.9 | -392.5 | |||||||||||||||||||
cash-flows.row.debt-repayment | -65 | -25 | -48 | -38 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.5 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -0.5 | |||||||||||||||||||
cash-flows.row.dividends-paid | -206.97 | -201.5 | -202.7 | -102.3 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 15.5 | -1.1 | 10 | 12.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -215.97 | -210.2 | -240.8 | -127.4 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.53 | 0.4 | 0.9 | -1.1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 105.47 | 626.7 | -67.7 | 180 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7750.42 | 2158.9 | 1504.5 | 1572.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7644.95 | 1532.2 | 1572.2 | 1392.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 890.65 | 1050.5 | 861 | 701.1 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 542.57 | 676.6 | 533.3 | 495 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5182.87 | 4973.5 | 4298.5 | 3935.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1479.99 | 1460.4 | 1020.5 | 897.3 | |||||||||||||||||||
income-statement-row.row.gross-profit | 3702.89 | 3513.1 | 3278.1 | 3038.3 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 571.7 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 48.23 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 2586.71 | 2443.5 | 2312.2 | 2116 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4066.7 | 3903.9 | 3332.7 | 3013.3 | |||||||||||||||||||
income-statement-row.row.interest-income | 19.62 | 23.8 | 25.5 | 17.7 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 89.4 | 175.1 | 159.4 | 173.2 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 1239.16 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 1136.69 | 1069.6 | 1003.5 | 925.9 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 1201.43 | 1159 | 989.9 | 915.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 136.17 | 134.4 | 109.5 | 117.8 | |||||||||||||||||||
income-statement-row.row.net-income | 1074.77 | 1036.9 | 900.7 | 797.8 |
Häufig gestellte Frage
Wie hoch ist die Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) Gesamtvermögen?
Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) Gesamtvermögen ist 7328195368.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 2705694560.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.714.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 0.538.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.207.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.219.
Was ist der Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 1036918058.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 172558561.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 2443472552.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 1635420861.000.